These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 19662218)

  • 21. Prognostic value of elevated preoperative serum CA125 in ovarian tumors of low malignant potential: a multinational collaborative study (ANZGOG0801).
    Tang A; Kondalsamy-Chennakesavan S; Ngan H; Zusterzeel P; Quinn M; Carter J; Leung Y; Obermair A
    Gynecol Oncol; 2012 Jul; 126(1):36-40. PubMed ID: 22370601
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The diagnostic value of determination of serum GOLPH3 associated with CA125, CA19.9 in patients with ovarian cancer.
    Fan HY; Duan DM; Liu YF
    Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):4039-4044. PubMed ID: 29028099
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A multiplex platform for the identification of ovarian cancer biomarkers.
    Boylan KLM; Geschwind K; Koopmeiners JS; Geller MA; Starr TK; Skubitz APN
    Clin Proteomics; 2017; 14():34. PubMed ID: 29051715
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative proteomics of ovarian epithelial tumors.
    An HJ; Kim DS; Park YK; Kim SK; Choi YP; Kang S; Ding B; Cho NH
    J Proteome Res; 2006 May; 5(5):1082-90. PubMed ID: 16674097
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: potential use in diagnosis and prognosis.
    Kozak KR; Amneus MW; Pusey SM; Su F; Luong MN; Luong SA; Reddy ST; Farias-Eisner R
    Proc Natl Acad Sci U S A; 2003 Oct; 100(21):12343-8. PubMed ID: 14523236
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma.
    Han C; Bellone S; Siegel ER; Altwerger G; Menderes G; Bonazzoli E; Egawa-Takata T; Pettinella F; Bianchi A; Riccio F; Zammataro L; Yadav G; Marto JA; Penet MF; Levine DA; Drapkin R; Patel A; Litkouhi B; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Santin AD
    Gynecol Oncol; 2018 Jun; 149(3):585-591. PubMed ID: 29572027
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Clinical value of serum CA19-9, CA125 and CP2 in mucinous ovarian tumor: a retrospective study of 273 patients].
    Dong L; Cui H; Li XP; Sun LF; Chang XH; Liang XD; Zhu HL
    Zhonghua Fu Chan Ke Za Zhi; 2008 Jan; 43(1):5-8. PubMed ID: 18366923
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comprehensive allelotype study of ovarian tumors of low malignant potential: potential differences in pathways between tumors with and without genetic predisposition to invasive carcinoma.
    Nakayama K; Takebayashi Y; Namiki T; Tamahashi N; Nakayama S; Uchida T; Miyazaki K; Fukumoto M
    Int J Cancer; 2001 Nov; 94(4):605-9. PubMed ID: 11745452
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of novel candidate plasma metabolite biomarkers for distinguishing serous ovarian carcinoma and benign serous ovarian tumors.
    Buas MF; Gu H; Djukovic D; Zhu J; Drescher CW; Urban N; Raftery D; Li CI
    Gynecol Oncol; 2016 Jan; 140(1):138-44. PubMed ID: 26521694
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Osteopontin, Macrophage Migration Inhibitory Factor and Anti-Interleukin-8 Autoantibodies Complement CA125 for Detection of Early Stage Ovarian Cancer.
    Guo J; Yang WL; Pak D; Celestino J; Lu KH; Ning J; Lokshin AE; Cheng Z; Lu Z; Bast RC
    Cancers (Basel); 2019 Apr; 11(5):. PubMed ID: 31035430
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Complementary Longitudinal Serum Biomarkers to CA125 for Early Detection of Ovarian Cancer.
    Simmons AR; Fourkala EO; Gentry-Maharaj A; Ryan A; Sutton MN; Baggerly K; Zheng H; Lu KH; Jacobs I; Skates S; Menon U; Bast RC
    Cancer Prev Res (Phila); 2019 Jun; 12(6):391-400. PubMed ID: 30967390
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Afamin and apolipoprotein A-IV: novel protein markers for ovarian cancer.
    Dieplinger H; Ankerst DP; Burges A; Lenhard M; Lingenhel A; Fineder L; Buchner H; Stieber P
    Cancer Epidemiol Biomarkers Prev; 2009 Apr; 18(4):1127-33. PubMed ID: 19336561
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum Anti-PDLIM1 Autoantibody as Diagnostic Marker in Ovarian Cancer.
    Qiu C; Duan Y; Wang B; Shi J; Wang P; Ye H; Dai L; Zhang J; Wang X
    Front Immunol; 2021; 12():698312. PubMed ID: 34489945
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oviductal glycoprotein (OVGP1, MUC9): a differentiation-based mucin present in serum of women with ovarian cancer.
    Maines-Bandiera S; Woo MM; Borugian M; Molday LL; Hii T; Gilks B; Leung PC; Molday RS; Auersperg N
    Int J Gynecol Cancer; 2010 Jan; 20(1):16-22. PubMed ID: 20130498
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Borderline ovarian tumours: retrospective analysis of twenty-one cases.
    Saygili U; Uslu T; Erten O; Doğan E
    Eur J Gynaecol Oncol; 1998; 19(2):182-5. PubMed ID: 9611063
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.
    Karlsen MA; Sandhu N; Høgdall C; Christensen IJ; Nedergaard L; Lundvall L; Engelholm SA; Pedersen AT; Hartwell D; Lydolph M; Laursen IA; Høgdall EV
    Gynecol Oncol; 2012 Nov; 127(2):379-83. PubMed ID: 22835718
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma.
    Morales-Vásquez F; Pedernera E; Reynaga-Obregón J; López-Basave HN; Gómora MJ; Carlón E; Cárdenas S; Silva-Ayala R; Almaraz M; Méndez C
    J Ovarian Res; 2016 Jul; 9(1):41. PubMed ID: 27388275
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer.
    Jones MB; Krutzsch H; Shu H; Zhao Y; Liotta LA; Kohn EC; Petricoin EF
    Proteomics; 2002 Jan; 2(1):76-84. PubMed ID: 11788994
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Microheterogeneity of transthyretin in serum and ascitic fluid of ovarian cancer patients.
    Gericke B; Raila J; Sehouli J; Haebel S; Könsgen D; Mustea A; Schweigert FJ
    BMC Cancer; 2005 Oct; 5():133. PubMed ID: 16225703
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preoperative determination of several serum tumor markers in patients with primary epithelial ovarian carcinoma.
    Kudoh K; Kikuchi Y; Kita T; Tode T; Takano M; Hirata J; Mano Y; Yamamoto K; Nagata I
    Gynecol Obstet Invest; 1999; 47(1):52-7. PubMed ID: 9852392
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.